Contingent Liabilities and Commitments (Details Textual) - USD ($) $ in Thousands |
1 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Apr. 29, 2019 |
Dec. 18, 2017 |
Aug. 31, 2017 |
Oct. 31, 2016 |
Mar. 31, 2015 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Dec. 31, 2016 |
Aug. 06, 2018 |
|
| Statement Line Items [Line Items] | |||||||||
| Company accrued in other accounts payable | $ 425 | ||||||||
| Upfront payments | $ 1,000 | ||||||||
| Motor lease expenses | 56 | $ 58 | |||||||
| Payment of award expenses | $ 14 | ||||||||
| Personal damages | 20 | ||||||||
| Damages claims | $ 33 | ||||||||
| Distribution and supply agreement, description | The Company is entitled to €1,500 upon execution of the agreement plus milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) €300 upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and €300 upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between €750 and €1,600 following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between €300 and up to €4,025 upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson. On January 25, 2018 the Company received a first payment of approximately USD 2,200 from Gebro and in August 2018 received the approximately USD 350 upon reaching the first milstone. | ||||||||
| Lease payments per month | $ 5 | ||||||||
| Lease term | The lease is for a period ending April 2021. | ||||||||
| Additional milestone payment | $ 2,000 | ||||||||
| Chong Kun Dang [Member] | |||||||||
| Statement Line Items [Line Items] | |||||||||
| Upfront payments | $ 500 | $ 500 | |||||||
| Upfront payments, additional | $ 2,500 | ||||||||
| Royalty payments, percentage | 23.00% | ||||||||
| Cipher [Member] | |||||||||
| Statement Line Items [Line Items] | |||||||||
| Upfront payments | $ 1,292 | ||||||||
| Royalty payments, percentage | 16.50% | ||||||||
| NIS [Member] | |||||||||
| Statement Line Items [Line Items] | |||||||||
| Payment of award expenses | $ 50 | ||||||||
| Personal damages | $ 73 | ||||||||
| Damages claims | 125 | ||||||||
| Canadian Dollar [Member] | Cipher [Member] | |||||||||
| Statement Line Items [Line Items] | |||||||||
| Upfront payments | $ 1,650 | ||||||||
| Upfront payments, additional | $ 2,000 | ||||||||
| Euro [Member] | |||||||||
| Statement Line Items [Line Items] | |||||||||
| Concession commission | 25 | ||||||||
| Total royalties | $ 850 | ||||||||
| Patent agreement, description | The patent under the agreement, as follows: (i) € 50 upon initiation of Phase I studies; (ii) € 100 upon initiation of Phase II studies; (iii) € 200 upon initiation of Phase III studies; and (iv) € 500 upon marketing approval by any regulatory authority. | ||||||||
| Royalty payments, percentage | 10.00% | ||||||||